Recommandations Du Comité De Cancérologie De L’association Française D’urologie (CC-AFU) Pour La Bonne Pratique Des Instillations Intravésicales De Mitomycine C, D’épirubicine Et De BCG Pour Le Traitement Des Tumeurs De La Vessie N’infiltrant Pas Le Muscle (TVNIM)

Introduction. - Intravesical instillations of mitomycin C, epirubicin and BCG are considered as the standard treatment for most patients diagnosed with non-muscle invasive bladder cancer. These guidelines aim to optimize the adjuvant intravesical treatment in order to increase the efficacy and lower the morbidity associated with its administration. Methods. - We conducted a daily practice survey, an online search of available national regulation recommendations and of published guidelines. A bibliography search in French and English using Medline (R) and Embase (R) with the keywords "BCG "; "mitomycin C "; "epirubicin "; "bladder "; "complication "; "toxicity "; "adverse reaction "; "prevention " and "treatment " was performed November 2021. Results. - Patient information should be given by the attending physician before the first intravesical instillation. A medical exam to look for specific contraindications is also mandatory to select adequate candidates. Intravesical instillations should be delivered in health-care centers where urologic endoscopic procedures are routinely performed. Attending urologist or specialized nurse should check for negative pretreatment urine test. Intravesical instillation can only be delivered after bladder catheter has been inserted in the bladder without any injury of the lower urinary tract. The pharmaceutical agent should be kept in the bladder for two hours. Finally, voiding within the 6 hours following intravesical instillations should be done in the sitting position and the patient should drink at least 2 liters of water per day for 2 days. Conclusion. - The delivery of intravesical instillations of mitomycin C, epirubicin and BCG should follow a standardized procedure for better efficacy and lower morbidity. (c) 2022 Elsevier Masson SAS. All rights reserved.